izalontamab brengitecan   Click here for help

GtoPdb Ligand ID: 14566

Synonyms: BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
Approved drug
izalontamab brengitecan is an approved drug
Compound class: Antibody
Comment: Izalontamab brengitecan (BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) that is designed to deliver the camptothecin derived topoisomerase I inhibitor Ed-04 payload to tumour cells that express EGFR and HER3 receptor tyrosine kinases. The drug carries of eight toxin molecules per antibody (SI-B001) molecule [7,9]. Peptide sequences for the heavy and light chains of the parental antibody (obtained from the INN record) are claimed in patent US10919977, specifically for the clone named SI-1X6.4 [3].
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2026)
International Nonproprietary Names Click here for help
INN number INN
12678 izalontamab brengitecan
Synonyms Click here for help
BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1484
Other databases
GtoPdb PubChem SID 530846814
Search PubMed clinical trials izalontamab brengitecan
Search PubMed titles izalontamab brengitecan
Search PubMed titles/abstracts izalontamab brengitecan